RA Capital Management and OrbiMed

Selected healthcare news for the capital firm - RA Capital Management, and the company - OrbiMed. We have 59 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
8/17/2021 Biotherapeutics Startup GentiBio Receives $157 mln in Series A Round ... OrbiMed, Avidity Partners, JDRF T1D Fund, RA Capital Management, and the Seattle Children‚Aos Research Institute. GentiBio has completely and exclusively designed its Tregs platform itself with the aim of overcoming limitations in T-cell therapy. The company is a leader in solving problems caused by diseases which include overactivity or troubled immune systems. With this investment, GentiBio will advance the functional treatment of Type 1 Diabetes (T1D). At the ...
8/12/2021 GentiBio raises $157m to develop Treg therapies for autoimmune diseases GentiBio plans to commence trials of its clinical candidate for type 1 diabetes before the end of the year. Credit: gerlos / Flickr. GentiBio has raised $157m in a Series A funding round led by Matrix Capital Management to progress its new pipeline of engineered regulatory T cell (Treg) treatments in immunology.Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, Novartis Venture Fund and Seattle Children‚Aos Research Institute participated ...
8/11/2021 GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation ... OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children's Research Institute. The company's unique platform aspires to functionally cure autoimmune, alloimmune, autoinflammatory, and allergic diseases using novel technologies that precisely redirect stable, potent engineered Tregs to tissues damaged by abnormal immune responses. GentiBio, leveraging its highly differentiated platform, is able to create multiple, tunable Treg phenotypes from more abundant autologous and allogeneic cell sources that can be manufactured ...
8/11/2021 GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation BOSTON, Aug. 11, 2021 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced it has closed on a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children's Research Institute. The company's unique platform aspires to functionally ...
8/11/2021 Digital Health News, Summary of Financing in the Past Week; August 9 Zentera Therapeutics: Zentera Therapeutics is a Shanghai, China-based biopharmaceutical company aiming to bring cancer therapies to China. Zentera Therapeutics, has raised $75 million in Series B funding. OrbiMed Advisors Asia and Tybourne Capital Management led the round, joined by Avidity Partners, Casdin Capital, and Surveyor Capital. Read more PepGen: PepGen is a Boston-based maker of therapies for neurologic diseases. PepGen has raised $112.5 million. Investors included RA Capital ...
8/11/2021 GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation PR Newswire BOSTON GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced it has closed on a Series A financing generating immediate proceeds of $157 million , led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children's Research Institute. The company's unique platform aspires to functionally cure autoimmune, alloimmune, autoinflammatory ...
7/7/2021 Canadian start-up raises $60M to advance novel blood test for cancer ... OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management. The funding will help Adela bring its blood test closer to the marketplace, with initial applications across the cancer care spectrum, from early detection to disease monitoring. ‚AuAdela‚Aos technology has the potential to revolutionize how we detect and diagnose disease,‚Au says David Scheer, board chair and founding member of Adela. ‚AuWe envision a future in which a single, accessible ...
6/23/2021 Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases Globe Newswire ... OrbiMed, Deerfield Management, Decheng Capital, and RA Capital ManagementTORONTO, June 23, 2021 (GLOBE NEWSWIRE) -- Adela (formerly DNAMx) has launched with $60 million USD in Series A financing to enable the detection of cancer and other high-morbidity, high-mortality conditions through a blood test that harnesses the potential of the methylome. Adela√¢¬A¬os genome-wide methylation enrichment technology offers the potential to detect many diseases with a single ...
6/23/2021 Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer an‚Ķ Globe Newswire ... OrbiMed, Deerfield Management, Decheng Capital, and RA Capital ManagementTORONTO, June 23, 2021 (GLOBE NEWSWIRE) ‚Ai Adela (formerly DNAMx) has launched with $60 million USD in Series A financing to enable the detection of cancer and other high-morbidity, high-mortality conditions through a blood test that harnesses the potential of the methylome. Adela‚Aos genome-wide methylation enrichment technology offers the potential to detect many diseases with a single ...
6/23/2021 Liquid Biopsy Startup Adela Launches With $60M Series A Financing Round | Genomeweb NEW YORK ‚Ai Adela, a Toronto-based startup looking to develop a liquid biopsy test based on detecting DNA methylation, said on Wednesday that it has raised $60 million in Series A financing.F-Prime Capital led the round, joined by OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management."The immense potential of our core technology has been demonstrated across 10 different cancer types," Scott Bratman, Adela's cofounder and ...
4/28/2021 Liquid biopsy co Nucleix raises $55m ... RA Capital Management, with participation from new investors BlackRock, Lilly Asia Ventures, LYFE Capital and MILFAM. Existing investors participating in the round included OrbiMed, Aurum Ventures, DSC Investment, OCI Bio Investments and Zohar Zisapel.Nucleix will use the latest investment to speed up development of its methylation technology, known as EpiCheck®, and to develop Lung EpiCheck, its lead product for the early detection of lung cancer.With offices in ...
4/21/2021 Janux Therapeutics raises funding to advance T cell engager treatments ... RA Capital Management, the financing round was joined by new investors BVF Partners, EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital.Janux‚Aos current investors, OrbiMed, Avalon Ventures, and Bregua, also took part. T cell engager immunotherapy portfolio includes a PSMA-TRACTr, EGFR-TRACTr and TROP2-TRACTr.Janux Therapeutics president and CEO David Campbell said: ‚AuThis commitment from a world-class syndicate of ...
4/20/2021 Adagio gets $336m funding to advance antibody treatment for Covid-19 ... RA Capital Management, an investment advisor focused on life-sciences and healthcare sectors.New investors including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor have participated in the funding round.Also, existing investors Fidelity Management & Research Co., OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds have participated in the financing.The US-based biotechnology company intends to use the funding ...
4/20/2021 Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials ¬i Proceeds support advancement of the company¬is pipeline of TRACTr drug candidates into clinical trials ¬i Funding round supported by top-tier crossover investor syndicate, including RA Capital Management, BVF Partners L.P., EcoR1 Capital, Janus Henderson Investors, Logos Capital, OrbiMed, Samsara BioCapital, Surveyor Capital, and other investors SAN DIEGO, April ...
4/20/2021 Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials | Financial Buzz Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company). Janux‚Aos existing investors, OrbiMed, Avalon Ventures, and Bregua, also participated. The proceeds of the financing will help support the advancement of Janux‚Aos pipeline of ...
4/19/2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 | Business Wire Business Wire WALTHAM, Mass.--( BUSINESS WIRE )--Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336 million Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners ...
4/19/2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 Yahoo News ... RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds also participated in the financing.The financing will support continued advancement of ADG20, Adagio‚Aos lead clinical candidate being developed as a single agent for both the treatment ...
4/19/2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 ... RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds also participated in the financing. The financing will support continued advancement of ADG20, Adagio‚Aos lead clinical candidate being developed as a single agent for both the treatment ...
4/19/2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 | Financial Buzz Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336 million Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds ...
4/19/2021 Adagio Raises $336 Million to Support Development of COVID-19 Antibody Candidate - PharmaVOICE : PharmaVOICE ... RA Capital Management, in tandem with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space.Other existing investors that funneled funding into the new series C financing included Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab, and Omega Funds.In a statement made by Adagio, the company says it will continue to advance ...
4/8/2021 Liquid biopsy maker Nucleix rakes in $55M to develop blood tests to detect lung cancer early | FierceBiotech FierceBiotech It‚Aos full steam ahead for Nucleix‚Aos blood test for lung cancer detection, thanks to an influx of cash in the Israeli company‚Aos latest round of funding.The liquid biopsy maker closed its oversubscribed $55 million financing on April 7. RA Capital Management led the round, with additional participation from new and existing investors including BlackRock-managed funds and accounts, Lilly Asia Ventures, OrbiMed and more.The financial ...
4/7/2021 Nucleix Nabs $55M For Lung Cancer Detection Nucleix Nabs $55M For Lung Cancer Detection San Diego-based Nucleix , a startup which is developing liquid biopsy technology for early detection of lung cancer, has raised $55M in a funding round, the company announced this morning. The company said the funding was led by RA Capital Management, and also included BlackRock, Lilly Asia Ventures, LYFE Capital and MILFAM, plus OrbiMed, Aurum Ventures, The story you have requested is only ...
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines | Business Wire Business Wire ALAMEDA, Calif.--( BUSINESS WIRE )--Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures ...
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop "CRISPR by Design" Platform and Pipeline of Breakthrough Genetic Medicines Yahoo News ... OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment firm also joined the syndicate. As part of the financing, Behzad Aghazadeh, managing partner at Avoro Ventures and Avoro Capital Advisors, and Carl L. Gordon, managing partner at OrbiMed Advisors, will join Scribe‚Aos Board of Directors.The ...
3/31/2021 Scribe Raises $100 Million to Further Develop Its ‚ÄúCRISPR by Design‚Äù Platform Rare Daily Staff Scribe Therapeutics completed an oversubscribed $100 million series B financing to continue developing its ‚AuCRISPR by Design‚Au platform and its pipeline of genetic medicines. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment ...